“This offer – the continuation of the memorandum – will be sufficient to ensure the completion of the second administrations to be held in the next few weeks over the entire regional region.”
According to this new offer, it is thus possible – in the published conclusion – to resume work from Tuesday, April 27, AstraZeneca vaccine is also given as a “first dose,” according to previously issued indications by category.
Meanwhile, the largest batch of vaccines so far arrived in Italy in one fell swoop – 2.2 million doses of Pfizer, between Tuesday and Wednesday – the campaign recorded in recent days can be relaunched and somewhat paced after the previous ones (335,000 and 263,000 administrations respectively daily) Sunday and Monday). The 20 million doses distributed over the territories have passed, which have injected about 90% and are now risking shortages again.
In 7 days, 5 million doses will arrive, another 15 million by mid-May, 31 in June, according to estimates by the Emergency Committee, which believes that a goal of half a million injections per day is still possible in the short term.. Meanwhile, more than 13 million Italians were vaccinated with at least one dose, 21.7% of the population. It is worth noting the partial or total level of protection that Great Britain reached in February, in a state of strict lockdown completely, while most of the country reopened in Italy for two days.
Among the citizens who received at least one dose, 65.5% are over the age of 70: a clear sign that the campaign is accelerating. According to Roberto Cauda, an infectious disease specialist at the Gemelli Polyclinic in Rome, “We will have to wait until the end of May to see the effect of vaccinations on infections and victims, in the first ten days of May to see the extent of the reopening of infections.”
“According to different mathematical models, we will achieve herd immunity in the fall,” adds the professor. In October, the current pace of vaccinations continues.
Meanwhile, Janssen, the producer of Johnson & Johnson, acknowledges the causal role of its single-dose preparation in very rare cases of thrombosis, which has been banned in the United States. And from the United States comes a troubling number: More than 5 million people did not show up for a second dose of Pfizer or Moderna – the vaccines by far the most widely used -, 8% of those who received the first. Main reasons: Fear of side effects or the idea of actually adequate protection.
© Reproduction reserved